Home > Publications Database > Neurotropic growth factors and glycosaminoglycan based matrices to induce dopaminergic tissue formation. > print

001     138111
005     20240808134014.0
024 7 _ |a 10.1016/j.biomaterials.2015.07.029
|2 doi
024 7 _ |a pmid:26222283
|2 pmid
024 7 _ |a 0142-9612
|2 ISSN
024 7 _ |a 1878-5905
|2 ISSN
024 7 _ |a altmetric:108386780
|2 altmetric
037 _ _ |a DZNE-2020-04433
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Schurig, Katja
|0 P:(DE-2719)2810324
|b 0
|e First author
|u dzne
245 _ _ |a Neurotropic growth factors and glycosaminoglycan based matrices to induce dopaminergic tissue formation.
260 _ _ |a Amsterdam [u.a.]
|c 2015
|b Elsevier Science
264 _ 1 |3 print
|2 Crossref
|b Elsevier BV
|c 2015-10-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1723117195_2209
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Current cell replacement therapies in Parkinson's disease (PD) are limited by low survival of transplanted cell and lacking regeneration of neuronal circuitries. Therefore, bioartificial cell carriers and growth/differentiation factors are applied to improve the integration of transplants and maximize newly generated and/or residual dopaminergic function. In this work, biohybrid poly(ethylene glycol) (starPEG)-heparin hydrogels releasing fibroblast growth factor 2 (FGF-2) and glial-derived neurotrophic factor (GDNF) were used to trigger dopaminergic tissue formation by primary murine midbrain cells in vitro. Matrix-delivered FGF-2 enhanced cell viability while release of GDNF had a pro-neuronal/dopaminergic effect. Combined delivery of both factors from the glycosaminoglycan-based matrices resulted in a tremendous improvement in survival and maturation capacity of dopaminergic neurons as obvious from tyrosine hydroxylase expression and neurite outgrowth. The reported data demonstrate that glycosaminoglycan-based hydrogels can facilitate the administration of neurotrophic factors and are therefore instrumental in potential future treatments of PD.
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 0
542 _ _ |i 2015-10-01
|2 Crossref
|u https://www.elsevier.com/tdm/userlicense/1.0/
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Glial Cell Line-Derived Neurotrophic Factor
|2 NLM Chemicals
650 _ 7 |a Glycosaminoglycans
|2 NLM Chemicals
650 _ 7 |a Hydrogels
|2 NLM Chemicals
650 _ 7 |a Nerve Growth Factors
|2 NLM Chemicals
650 _ 7 |a Fibroblast Growth Factor 2
|0 103107-01-3
|2 NLM Chemicals
650 _ 7 |a Polyethylene Glycols
|0 3WJQ0SDW1A
|2 NLM Chemicals
650 _ 7 |a Heparin
|0 9005-49-6
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Cell Differentiation: drug effects
|2 MeSH
650 _ 2 |a Cell Survival: drug effects
|2 MeSH
650 _ 2 |a Cells, Cultured
|2 MeSH
650 _ 2 |a Dopaminergic Neurons: cytology
|2 MeSH
650 _ 2 |a Dopaminergic Neurons: drug effects
|2 MeSH
650 _ 2 |a Drug Liberation
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Fetus: cytology
|2 MeSH
650 _ 2 |a Fibroblast Growth Factor 2: pharmacology
|2 MeSH
650 _ 2 |a Glial Cell Line-Derived Neurotrophic Factor: pharmacology
|2 MeSH
650 _ 2 |a Glycosaminoglycans: pharmacology
|2 MeSH
650 _ 2 |a Heparin: chemistry
|2 MeSH
650 _ 2 |a Hydrogels: chemical synthesis
|2 MeSH
650 _ 2 |a Mesencephalon: cytology
|2 MeSH
650 _ 2 |a Mice, Inbred C57BL
|2 MeSH
650 _ 2 |a Nerve Growth Factors: pharmacology
|2 MeSH
650 _ 2 |a Neural Stem Cells: cytology
|2 MeSH
650 _ 2 |a Neural Stem Cells: drug effects
|2 MeSH
650 _ 2 |a Neurites: drug effects
|2 MeSH
650 _ 2 |a Neurites: metabolism
|2 MeSH
650 _ 2 |a Neuroglia: cytology
|2 MeSH
650 _ 2 |a Neuroglia: drug effects
|2 MeSH
650 _ 2 |a Polyethylene Glycols: chemical synthesis
|2 MeSH
650 _ 2 |a Tissue Engineering: methods
|2 MeSH
700 1 _ |a Zieris, Andrea
|b 1
700 1 _ |a Hermann, Andreas
|0 P:(DE-2719)2811732
|b 2
|u dzne
700 1 _ |a Freudenberg, Uwe
|b 3
700 1 _ |a Heidel, Sabine
|b 4
700 1 _ |a Grimmer, Milauscha
|b 5
700 1 _ |a Storch, Alexander
|0 P:(DE-2719)9000306
|b 6
|u dzne
700 1 _ |a Werner, Carsten
|0 P:(DE-HGF)0
|b 7
|e Corresponding author
773 1 8 |a 10.1016/j.biomaterials.2015.07.029
|b : Elsevier BV, 2015-10-01
|p 205-213
|3 journal-article
|2 Crossref
|t Biomaterials
|v 67
|y 2015
|x 0142-9612
773 _ _ |a 10.1016/j.biomaterials.2015.07.029
|g Vol. 67, p. 205 - 213
|0 PERI:(DE-600)2004010-6
|q 67<205 - 213
|p 205-213
|t Biomaterials
|v 67
|y 2015
|x 0142-9612
856 4 _ |u https://pub.dzne.de/record/138111/files/DZNE-2020-04433_Restriced.pdf
856 4 _ |u https://pub.dzne.de/record/138111/files/DZNE-2020-04433_Restriced.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:138111
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2810324
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2811732
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)9000306
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2015
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BIOMATERIALS : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BIOMATERIALS : 2017
920 1 _ |0 I:(DE-2719)5000014
|k AG Storch
|l Non-Motor Symptoms in Parkinson's disease
|x 0
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)5000014
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21